Pharmaceutical giant Roche boosted its earnings outlook, fueled by strong sales of its innovative cancer, immunology, and diagnostic products. This success highlights a broader investment opportunity in leading drugmakers with powerful research and development engines poised for growth.
Published on October 23
These companies are developing cutting-edge treatments that could revolutionise healthcare. When clinical trials succeed, stock prices can soar dramatically.
Healthcare demand remains strong regardless of economic conditions. People need medicines whether times are good or tough, making these stocks naturally defensive.
Professional analysts handpicked these companies based on their R&D strength and market execution. You're getting access to institutional-quality research and insights.
This group focuses on innovative drugmakers whose value is driven by powerful research and development engines. The investment rationale centres on the potential for sustained revenue growth from successful drug pipelines, which can provide resilience against wider economic cycles due to inelastic demand for healthcare.
These companies invest heavily to discover, develop, and commercialise novel treatments, particularly in high-growth areas like oncology, immunology, and diagnostics. The healthcare sector demonstrates remarkable resilience, with sustained demand for innovative medical treatments even in challenging economic climates.
This basket was curated to include established leaders and clinical-stage biotechs with promising therapies. Each company was handpicked by professionals based on their strong pipelines in high-demand therapeutic areas and successful market execution potential.
Summary and investor takeaways for the provided market capitalisation breakdown of the basket.
BMY: $90.66B
REGN: $61.40B
EXAS: $12.00B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+148.75%
On average, analysts expect assets in this group to grow 148.75% over the next year.
14 of 14 assets in this group are rated Buy by professional analysts.
